Ever since its approval in 1976, dacarbazine represents the standard of care for the treatment of patients with metastatic melanoma, however, only a minority of melanoma patients responds to dacarbazine treatment. This article presents clinical evidence that the combination of dacarbazine with the tumortargeting immunocytokine L19-IL2 (a biopharmaceutical consisting of the human recombinant antibody L19, specific to the alternatively-spliced EDB domain of fibronectin, fused to human interleukin-2) is well tolerated in patients with metastatic melanoma and can induce long-lasting objective responses in a subset of patients. Author Manuscript Published OnlineFirst on October 25, 2011; DOI: 10.1158/1078-0432.CCR-11-1203 6 dacarbazine is safe and shows encouraging signs of clinical activity in metastatic melanoma patients. This combination therapy is currently evaluated in a randomized phase II trial with metastatic melanoma patients.
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INTRODUCTION
Melanoma is the most aggressive type of skin cancer, causing 8,700
estimated deaths per year in the U.S. alone [1, 2] , and having a very poor prognosis, well reflected in a 5-year survival rate of below 5% [3] .
Current therapy approaches for treating metastatic melanoma include cytotoxic chemotherapy, immunotherapy, and the combination of the two.
Until the recent approval of ipilimumab and vemurafenib, the melanoma therapy landscape was dominated by two agents, dacarbazine and Interleukin-2 [4, 5] . Dacarbazine is the only chemotherapeutic agent approved by FDA; when given as single agent, it shows response rates between 5% and 15% [6] . However, responses are rarely durable and most patients experience disease relapse after a few weeks or months [7] . Despite such modest efficacy, dacarbazine still represents the reference treatment of metastatic melanoma, chosen as comparative arm in many clinical trials [8] .
Some immunotherapeutic approaches have led to more durable responses in a small number of patients. In 1998, FDA approved high-dose bolus Interleukin-2 (HD IL2) for the treatment of metastatic melanoma, based on its ability to mediate durable and complete responses in a small subset of patients [9-11]. However, major toxicities associated with HD IL2 limit its administration to patients with excellent performance status [8] .
In consideration of the significant toxicities associated with IL2 treatment, monoclonal antibodies have been proposed as "vehicles" for the selective delivery of this immune-stimulatory cytokine to the tumor environment, thus sparing normal tissues [12] [13] [14] [15] . Reisfeld use of full immunoglobulins, featuring a C-terminal fusion of IL2 with the heavy chain of the IgG molecule [16] . This strategy has been moved to clinical trials in patients with neuroendocrine tumors [17] and melanoma [18, 19] , using antibodies specific to EpCAM and GD2-Ganglioside, respectively. Such approaches have shown good safety profile and favorable pharmacokinetics, but limited signs of antitumor activity [18, 19] . In order to avoid the generation of multi-functional therapeutic proteins featuring the simultaneous presence of an antigen-binding moiety, IL2, and of the Fc antibody portion which could cross-link the cytokine onto cells carrying Fcγ receptors, we constructed smaller fusion proteins between a human antibody in the single-chain variable Fragment (scFv) format and recombinant human IL2 [20] [21] [22] [23] . In particular, the monoclonal antibody L19, specific to the alternatively spliced extra-domain B (EDB) of fibronectin, appeared to be an ideal candidate for the pharmacodelivery of IL2, in view of its very limited binding to normal mature tissues and its ability to selectively localize to newly formed blood vessels in almost all cancers, irrespective of histopathology [22] . L19-IL2 had been administered as monotherapy to patients with renal cell carcinoma and other solid tumors in a Phase I/II study [23] , and the recommended dose (RD) for monotherapy was determined to be 22.5 Mio IU IL2 equivalents.
Here we report safety and activity results of the L19-IL2/dacarbazine combination therapy in 32 metastatic melanoma patients.
The clinical development of L19-IL2 in metastatic melanoma was justified not only by the previous reports of therapeutic activity of recombinant human IL2 in this indication [9, 10, 24] , but also by the preclinical observation that L19 
MATERIALS AND METHODS
Patient characteristics
In the dose-escalation part of the study, 3-4 patients were recruited into each of three sequential dosing cohorts. Doses were escalated using the following scheme: 10, 15 and 22. 
Study design and treatment
This was an open-label, non-randomized, Phase II study involving three centers in Germany and Italy. During the dose-escalation part, patients were enrolled in three sequential cohorts (3-4 subjects per cohort) corresponding to a fixed dose of dacarbazine and increasing doses of L19-IL2; subsequently, 22 patients were enrolled and treated at the confirmed RD. The Phase IIb
Step 1 part of the study is the first step of an optimal Simon two-step design, considering a type-one error rate of 5%, a power of 80%, a null hypothesis p 0 =0.10, and a target response rate p 1 =0.25. Assumption for continuation of enrollment in the following Phase IIb Step 2 part of the study, was that at least During the dose-escalation, the highest investigated dose level for which a dose-limiting toxicity (DLT) incidence in not more than one out of three patients is observed, was designated as RD. DLTs were defined using the 
RESULTS
Study design
Patients could receive up to 6 cycles of treatment (induction) with L19-IL2 and dacarbazine. Patients with stable or responding disease after induction could receive additional biweekly L19-IL2 administration, without dacarbazine, as maintenance therapy. Dose finding, pharmacokinetics, safety and tolerability All enrolled patients had progressing disease at the time of entering the study.
The median age at the start of treatment was 55 years, 23 patients were males and 9 females ( Table 1) . Patients enrolled in the dose-escalation part of the study were heavily pretreated, with 9/10 patients having received previous chemotherapy and 8/10 previous radiotherapy. Further details about baseline characteristics of the single patients (i.e., site of disease, prior treatments, mutational status) are given in the Supplementary Table 1.
The maximum tolerated dose (MTD), determined as 22.5 Mio IU in a previous monotherapy study [23] , was found to be safe also in combination with standard dacarbazine (1g/m 2 ), and none of the 10 patients enrolled in the dose-escalation part of the study experienced a drug-related DLT.
Pharmacokinetic evaluation was performed on all the Phase IIa patients. Overall, 32 out of 32 patients were evaluable for safety. Toxicity was manageable and reversible, with no serious unexpected suspected adverse reactions (SUSAR) and no treatment related deaths. The incidence of drugrelated adverse events by grade and System Organ Class (SOC) is listed in Table 2 . The most frequent adverse events included chills, fatigue and fever, which however were generally dose related and mild or moderate in severity. cytokine support] and a maintenance biotherapy (with low-dose IL2 and GM-CSF followed by intermittent pulses of decrescendo IL2 over 12 months) [30] .
Given the limited number of patients, it is of course premature to judge about the clinical significance of the therapeutic potential of L19-IL2 in melanoma.
However, the observation that more than 60% of the study patients were still alive 12 months from start of treatment is highly encouraging, considering that the median survival for pretreated melanoma patients is typically 6-9 months 21 treated patients revealing response rates between 5% and 27%. In contrast to chemotherapy-induced responses, IL2 based schedules seem to be able to produce durable remissions [33, 34] . Similar effects could be observed in some patients responding to L19-IL2; results from a larger ongoing trial with L19-IL2 will confirm if this trend is real.
The combined treatment with L19-IL2 plus dacarbazine was reasonably well tolerated, and all side effects encountered in the study were manageable and reversible. In comparison to HD IL2 therapy, which is recommended to be carried out only in hospitals with easy access to an intensive care facility, the infusion of L19-IL2 never resulted in severe adverse events necessitating intensive care support. Rather, the application of L19-IL2 plus dacarbazine could be performed on a regular hospital ward or even in an outpatient setting 
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The pharmacokinetic studies performed in this trial have confirmed a rapid clearance of L19-IL2 at the end of the infusion, in full analogy with the data observed in preclinical models [22, 23] and in patients treated with L19-IL2 as single agent [23] . This rapid clearance is a favorable property of L19-IL2, which helps minimizing systemic adverse events, while the immunocytokine exhibits long residence times on the neoplastic lesions [15, 22, 25] . While the AUC of L19-IL2 in serum increased as expected as a result of the administered dose in the different cohorts, the serum levels of dacarbazine and of its metabolite AICA did not change substantially. 
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